Table 4.
Case number | Age at death | Race/sex |
---|---|---|
AD-1 |
81 |
Male |
AD-2 |
83 |
Caucasian male |
AD-3 |
66 |
African American female |
Control-1 |
88 |
Caucasian female |
Control-2 | 94 | Caucasian male |
Samples were screened for presence of Hirano bodies, and were derived from patients with AD, or control subjects that had no known history of neurological disease and no neuropathological changes indicative of neurodegenerative disease at autopsy.